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Background: To define protein molecular characteristics of tumor cells prior to, and immediately following,
preoperative human epidermal growth factor receptor 2 (HER2)-targeted therapy that correlate with pathologic
complete response (pCR) or non response (no pCR) to preoperative HER2-directed therapy and chemotherapy.
Methods: This open-label, phase II study randomized patients with HER2-positive stage II or III invasive breast
cancer to trastuzumab, lapatinib, or both, 2 weeks prior to and during chemotherapy with FEC75 for 4 courses; then
paclitaxel 80 mg/m2 weekly for 12 courses, then surgery. Core needle biopsies were collected at baseline and after
2 weeks of anti-HER2 therapy prior to chemotherapy. Data were correlated with pCR, defined as absence of invasive
tumor in breast and lymph nodes.
Results: Of 100 enrolled patients, the analysis population included those who had surgery and received ≥75%
chemotherapy (78% [n = 78]). pCRs by arm are: trastuzumab (n = 26), 54% [n = 14]; lapatinib (n = 29), 45% [n = 13];
trastuzumab plus lapatinib (n = 23), 74% [n = 17]). Paired biopsy specimens were available for 49 patients (63%).
Tumor cells of patients with pCR in the trastuzumab or lapatinib treatment arms showed nonphosphorylated FOXO,
phosphorylated Stat5, and sparse signal-transduction protein network crosstalk representing different patterns of
connections with PI3K and autophagy proteins compared with no pCR.
Conclusion: In this exploratory study, pCR with preoperative anti-HER2 therapy and chemotherapy correlated with
the levels and phosphorylation status of specific baseline signal pathway proteins in tumor cells. These data may
provide candidate biomarkers to stratify initial treatment and potential combination therapies for future study.
Tissue preservation technology introduced here makes this procedure widely feasible.
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Despite treatment with an effective human epidermal
growth factor receptor 2 (HER2)-targeted agent and
chemotherapy, approximately 15% of early-stage breast
cancer patients relapse [1,2]. Furthermore, the patho-
logic complete response (pCR) rate to preoperative anti-
HER2-targeted therapy and chemotherapy is only 40%
to 60% [3]. The HER2 pathway, activated upon HER2
pairing with a partner protein, may be highly complex
depending on the partner, the configuration of down-
stream interconnections, and the state of alternative
pathways. This molecular complexity provides multiple
mechanisms with which the tumor may evade a therapy
targeted to a single pathway [4,5]. Trastuzumab binds
within domain IV of the extracellular domain of the HER2
homodimer, but HER2 may also heterodimerize with
other HER (ErbB) receptors and non-HER2 partners [4,5].
An effective treatment must target both extant pathways
and those activated after treatment. Active pathways are
identified by determining the phosphorylation state of
pathway proteins, which can be measured by reverse
phase protein microarray technology [6].
The objective of this study was to measure the activity
state of signal pathway proteins linked to HER2 signaling.
Part one evaluated the effect of combining anti-HER2
therapy with chemotherapy (totaling 26 weeks), measured
by the pCR rate after definitive surgery. Part two identified
the molecular networks involved in HER2 signaling at
baseline and how they were altered after two weeks
of anti-HER2 treatment alone. Serial biopsies were per-
formed to obtain proteomic data and other molecular
biomarker data. Clinical response and safety were also
assessed. Part three examined a new, room-temperature,
fixation solution.
Methods
Study design and patients
This open-label, phase II study (LPT109096; NCT00524303)
randomized patients with HER2-positive stage II or
III invasive breast cancer to trastuzumab, lapatinib, or
both.
Eligibility criteria for patients were: ≥18 years of
age; the presence of untreated, biopsy-proven, HER2-
positive (immunohistochemistry [IHC] 3+ or fluores-
cence in situ hybridization [FISH] ratio >2.2), American
Joint Commission on Cancer stage II or III invasive
breast cancer; Eastern Cooperative Oncology Group
(ECOG) performance status of 0 or 1; left ventricular
ejection fraction ≥50% and within the institutional range
of normal by echocardiogram or multi-gated acquisition
scan; the ability to swallow and retain oral medication
and to provide written informed consent. Adverse
events (AEs) were graded according to National Cancer
Institute Common Toxicity Criteria for AEs v3.0 [7].All data were verified by US Oncology Research and
GlaxoSmithKline (US Oncology 05-074, GlaxoSmithKline
LPT109096, registration NCT00524303). This study was
developed by the Breast Committee of US Oncology
Research with GlaxoSmithKline and, in accordance with
the precepts of the Helsinki Declaration, was approved by
the US Oncology Research central institutional review
board, Houston, TX, and clinically performed by US
Oncology Research.
Randomization and masking
In this open-label study, patients were randomly assigned
sequentially using a permutated block design (block size
of 6) to receive one of three anti-HER2 therapies: trastu-
zumab, lapatinib, or the combination (Figure 1). No strati-
fication factors were applied.
Procedures
Patients received anti-HER2 therapy for 14 days prior to
and during chemotherapy and continued until surgery:
trastuzumab 4 mg/kg loading dose, then 2 mg/kg weekly;
lapatinib 1500 mg daily, reduced to 1250 mg to reduce
diarrhea after a safety review of the first 45 patients en-
rolled (protocol amendment 3, approved April 15, 2009);
or trastuzumab given as above with lapatinib 1000 mg
daily, reduced to 750 mg daily during the 2-week run-in
period and FEC, then increased to 1000 mg during pac-
litaxel (protocol amendment 3, as above). Chemotherapy
was FEC75 intravenously once every 21 days for four
treatments, followed by paclitaxel 80 mg/m2 intravenously
for 12 weeks. Lapatinib was supplied by the sponsor, Glax-
oSmithKline. FEC75 includes 5-fluorouracil 500 mg/m2,
epirubicin 75 mg/m2, cyclophosphamide 500 mg/m2.
Postsurgical treatment was not specified.
Specimen collection and analysis
Core breast biopsies in the surgeon’s office were collected
at baseline and after the first 14 days of anti-HER2 treat-
ment, prior to chemotherapy: 4 cores at each time point.
One core from each time point was fixed in a protein/
phosphoprotein preservative developed by George Mason
University, Manassas, VA [8]. Frozen tissue sections were
prepared for laser capture microdissection of breast tumor
and/or stroma with analysis by reverse phase protein
microarray (Additional file 1). The protein endpoints eva-
luated are listed in Additional file 2: Table S1. Proteomics
analysis was performed by LAL and VE.
Statistical analysis
The sample size was based on feasibility, estimation of the
effect size, and to allow a sufficient number of samples for
biomarker evaluation. This study was not powered to
provide inference testing for the primary endpoint. Based
on a planned total sample size of 99 subjects (33 per
Figure 1 CONSORT diagram. aPatients who had surgery; bPatients with inevaluable tumor responses; cPatients who had surgery and had paired
biopsies for evaluation.
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increased response rate in the comparator, lapatinib, or
combination arm compared with the control arm, trastu-
zumab monotherapy, using a two-sided Fisher exact test
at the 5% significance level if the estimated pCR rates
in the comparator arms (lapatinib and the combination)
compared with the control arm were 75% and 50%,
respectively.
All randomized patients comprised the intention-to-
treat (ITT) population, regardless of whether they had re-
ceived treatment. The ITT-evaluable (ITT-E) population
consisted of ITT patients with evaluable tumor responses
who had received ≥75% of the planned FEC75 and pacli-
taxel and had surgery. The ITT-E was the primary analysis
population for the pCR endpoint. The safety population
was all randomized patients who received at least one
dose of study treatment.
pCR was estimated for each of the three treatment arms
for the ITT-E (primary endpoint) and ITT (sensitivity ana-
lysis) populations. Exact 95% confidence intervals (CIs) for
the pCR response rates in each treatment arm were cal-
culated. Further exploratory summaries by the subgroups
of hormone receptor (HR)-positive (defined as estrogen
receptor [ER]-positive and/or progesterone receptor [PR]-
positive) and HR-negative (defined as ER-negative and
PR-negative) were also examined.
Overall response rate (ORR) was calculated from the
review of best response of confirmed partial response
and CR only using Response Evaluation Criteria in Solid
Tumors 1.0.[9] Subjects with unknown or missingresponses were treated as non-responders. Estimates
and Fisher exact 95% CIs for the ORR in each treatment
group were calculated.
All biomarker analyses were conducted on the ITT-E
population. Wilcoxon-rank sum was used to calculate
group differences if the data were not normally distrib-
uted. Student t-test was used if the data were normally
distributed. P values <0.05 were considered significant; no
adjustment for multiple comparisons were made. Mean
centered data normalization was performed using Z-score
transformation. Spearman rho (SR) nonparametric cor-
relations between pairs of endpoints were calculated.
SR correlation statistics were used to determine which
protein endpoints were interacting, evidenced by coordi-
nated changes, in each treatment group, ie, either both
increased or decreased or both consistently changing in
opposite directions, after treatment. The interacting pro-
teins in the network using this standard approach were
correlated (p < 0.001) over a large range of the examined
network proteins. Ratios of pairs of interacting proteins
(documented to show statistically significant SR cor-
relation) in the signal pathway network showed signi-
ficant differences associated with pCR (Table 1). This
suggests activation or suppression of these pathways be-
fore or after treatment.
Results
Between August 13, 2007 and October 15, 2010, 100 pa-
tients at 17 clinical centers were enrolled. The ITT-E
population consisted of 78 patients and, of these, 49 had
Table 1 Protein signal pathway correlates of breast pCR
Analyte Treatment arm
(Baseline/Day 14)
Reverse phase protein microarray results Interpretation
pCR Breast Yes pCR p Value <0.05
Breast No
EGFR Tyr1068 Lapatinib arm Baseline Mean: Mean: p = 0.02c Phosphorylation of EGFR at Tyrosine 1068
occurs during receptor activation, leading
to downstream activation of growth and
pro-survival pathway proteins.
-0.66 -0.01
(n = 6) (n = 11)
FOXO1/03A Ratios All treatment arms
Baseline
FOXO is a transcription factor that functions
as a tumor suppressor. FOXO triggers cell
cycle arrest and apoptosis after it enters the
nucleus. Phosphorylation of FOXO (pFOXO)
causes export from the nucleus and
inactivates its tumor suppressor function.
Trastuzumab inhibits HER2+ cells by
reactivation of FOXO1A [15]
pPTEN:pFOXO Mean ratio: 2.79 Mean ratio:
0.04
p = 0.01b
(n = 27) (n = 22)
PI3K:pFOXO Mean ratio: 3.23 (n =
27)
Mean ratio p = 0.039
-0.2 (n = 22)
pStat5 Tyr694 Trastuzumab
arm day 14
Mean: Mean: p = 0.017b Stat5 is a transcription factor. After
phosphorylation by JAK2, pStat5 translocates
to the nucleus to initiate transcription of
e-cadherin, which promotes homotypic
adherence between breast cells and
basement membrane, i.e., normal behavior.
Absent nuclear pStat5 is a negative
prognostic factor [16,17]. Increased pStat
indicates transcription functionality in our
pCR subjects.
1.14 -0.49





Autophagy is a normal cellular process to
promote cell survival under stress (hypoxia,
nutrient deprivation, loss of adhesion).
Autophagy allows the cell to “self eat” to
generate ATP from cellular contents and
thereby survive in times of stress, starvation,
hypoxia, or chemotherapy. Autophagy is
regulated by a network of cell signaling
proteins, including mTOR, Beclin (upstream
markers), Bcl2, LC3B (downstream markers),
Atg5. Cells from patients classified as pCR
No appear to engage autophagy to survive in
the presence of treatment with trastuzumab,




LC3B-MMP14 LC3B-MMP14 p < 0.001
SR = 0.83
LC3B-Her2 LC3B-HER2 p < 0.001
SRa = 0.88
LC3B-Stat5 Tyr694 LC3B-pStat5 p < 0.001
SR = 0.84
aNonparametric Spearman’s rho (SR) correlation coefficient; bWilcoxon rank sum; cTwo sample t-test.
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Reasons for nonevaluability included no tumor in the
specimen, insufficient protein, or poor reproducibility
between replicates. Overall, most baseline characteristics
were balanced across the treatment arms (Table 2); how-
ever, there was an imbalance in HR status, with fewer
HR-negative patients in the combination arm. Clinical
data cut-off for these analyses was December 17, 2010
and occurred when the last patient reached the time of
surgery.
The pCR rate and 95% CIs for the primary ITT-E and
ITT populations are shown in Figure 2. In the ITT-E
population, the combination arm had a higher pCR rate
(74%) compared with the monotherapy arms (trastuzumab
and lapatinib, 54% and 45%, respectively). The exploratory
analysis of pCR rate for HR status was higher in HR-
negative patients than in the HR-positive patients in themonotherapy arms (Figure 2B and C). However, in con-
trast with other studies, there was no difference in the
pCR rate by HR status for the combination arm.
The ORR rates were similar in both the analysis popu-
lations (% [95% CI] for trastuzumab, lapatinib, and com-
bination arms, respectively): ITT-E 62 (40.6, 79.8), 76
(56.5, 87.7), 70 (47.1, 86.8); ITT, 61 (42.1, 77.1), 68 (49.5,
82.6), 61 (42.1, 77.1).
Biomarker findings that correlated with pCR in breast
in the 49 patients with matched baseline and post-
treatment samples are summarized in Table 1. None of
the individual baseline protein analytes were significantly
different across or between any treatment arms, con-
firming a lack of bias in pre-existing protein networks.
Individual endpoints as well as ratios between two end-
points were evaluated. When we evaluated each treat-
ment arm for individual analyte endpoints, the mean
Table 2 Baseline patient and tumor characteristics
Trastuzumab (n = 33) Lapatinib (n = 34) Trastuzumab + Lapatinib (n = 33) Total (N = 100)
Demographics
Age (years)
Mean (standard deviation) 51.1 (10.90) 50.8 (8.76) 49.2 (10.47) 50.4 (10.01)
Median (range) 54.0 (21-67) 52.0 (25-67) 50.0 (28-66) 51.5 (21-67)
<65 years, n (%) 31 (94) 32 (94) 30 (91) 93 (93)
≥65 years, n (%) 2 (6) 2 (6) 3 (9) 7 (7)
Menopausal status, n (%)
Postmenopausal 19 (58) 19 (56) 16 (48) 54 (54)
Sterile 5 (15) 5 (15) 6 (18) 16 (16)
Potential to bear children 9 (27) 10 (29) 11 (33) 30 (30)
Race, n (%)
African American 8 (24) 1 (3) 2 (6) 11 (11)
White/Caucasian 25 (76) 27 (79) 29 (88) 81 (81)
Other 0 6 (18) 2 (6) 8 (8)
Disease characteristics
Histology, n (%)
Adenocarcinoma 3 (9) 6 (18) 1 (3) 10 (10)
Medullary 0 0 1 (3) 1 (1)
Lobular invasive 0 1 (3) 2 (6) 3 (3)
Infiltrating ductal NOS 26 (79) 23 (68) 22 (67) 71 (71)
Other 4 (12) 4 (12) 7 (21) 15 (15)
Grade, n (%)
Not assessed 3 (9) 3 (9) 3 (9) 9 (9)
Well differentiated 0 3 (9) 1 (3) 4 (4)
Moderately 10 (30) 7 (21) 12 (36) 29 (29)
Poorly 20 (61) 21 (62) 17 (52) 58 (58)
Hormone receptor status, n (%)
Positive (ER + and/or PR+) 15 (45) 14 (41) 20 (61) 49 (49)
Negative (ER- and PR-) 18 (55) 20 (59) 13 (39) 51 (51)
HER2-IHC status, n (%)
0 2 (6) 0 1 (3) 3 (3)
1+ 0 0 1 (3) 1 (1)
2+ 4 (12) 3 (9) 0 7 (7)
3+ 22 (67) 26 (76) 26 (79) 74 (74)
Unknown 5 (15) 5 (15) 5 (15) 5 (15)
HER2-FISH status, n (%)
Positive 27 (82) 24 (71) 23 (70) 74 (74)
Negative 0 1 (3) 0 1 (1)
Unknown 6 (18) 9 (26) 10 (30) 25 (25)
Tumor size, n (%)
T2 22 (67) 12 (35) 22 (67) 56 (56)
T3 8 (24) 11 (32) 6 (18) 25 (25)
T4 3 (9) 8 (24) 5 (15) 16 (16)
Tx 0 3 (9) 0 3 (3)
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Table 2 Baseline patient and tumor characteristics (Continued)
TNM stage: regional nodes, n (%)
N0 18 (55) 11 (32) 13 (39) 42 (42)
N1 12 (36) 16 (47) 14 (42) 42 (42)
N2 3 (9) 7 (21) 6 (18) 16 (16)
Abbreviations: ER estrogen receptor, FISH fluorescence in situ hybridization, HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry, NOS not
otherwise specified, PR progesterone receptor, TNM tumor, node, metastasis.
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lapatinib arm were significantly higher in patients with
pCR (n = 11) compared with no pCR (n = 6; p < 0.02)
(Table 1). In the trastuzumab arm, the level of pStat5
Y694 post-treatment (day 14) was elevated in the pCR
cohort (p < 0.017). When protein analyte ratios were
compared with pCR for all treatment arms, the baseline
ratios of pPTEN to pFOXO (p < 0.01) and PI3K to
pFOXO (p < 0.039) were correlated with pCR (Table 1).
Two markers of autophagy were correlated with pCR:
Beclin1, an initiation marker, and LC3B, an autopha-
gosome marker. Tumors with pCR showed a linkage of
baseline LC3B with either HER2 or Stat5 (SR, p < 0.001);
whereas, tumors without pCR showed linkage of LC3B
with Beclin1 and MMP-14 (SR, p < 0.001). Data from the
three treatment arms were combined to determine
whether there was a SR protein endpoint linkage asso-
ciation with pCR. In the baseline breast tumor biopsy
specimens, there were fewer proteins with significant
correlations (22 proteins; p ≤ 0.05) compared with tumors
that did not achieve pCR (33 proteins; p ≤ 0.05) as shown
in Figure 3.
The safety and tolerability profile of trastuzumab and
lapatinib administered with FEC and paclitaxel in this
patient population was generally consistent with the
known profiles of each individual agent and the chemo-
therapies administered. No new safety signals were identi-
fied. A similar number of patients reported AEs (Table 3
and Additional file 3: Table S2) and serious AEs (SAEs;
Additional file 4: Table S3) in the three treatment arms.
No SAEs were reported by more than 3 (9%) patients in
any treatment group. No fatal AEs were reported on study
or within 30 days of last dose of study treatment.Figure 2 Rate of pCR for (A) ITT-E and ITT population (B) by hormone
receptor status in ITT population.Discussion
This small clinical discovery trial of preoperative HER2-
positive breast cancer confirmed previous reports that
dual-targeted anti-HER2 therapy was more effective
at inducing pCR than single-agent therapy [10-12]. The
safety profile was consistent with known profiles of the
individual agents. There are four important aspects of this
study. One, the study verifies a method to conduct exten-
sive proteomic analysis of signal pathways containing
the drug target before and after treatment with HER2-
directed therapies, before administration of any chemo-
therapy. Two, samples were collected for RNA, stem-cell
analysis, and DNA deep sequencing to be correlated with
proteomic data in subsequent reports. Three, this study
was performed in a community network, in practicing
oncologists’ offices, where the majority of patients usually
receive treatment. Four, this study confirmed the effec-
tiveness of preserving phosphoproteins in tissue samples
without freezing using a new one-step preservation
chemistry [8].
Proteins, and their post-translational modifications,
functionally mediate the pathways activated or amplified
by genetic abberrations. Although phosphoproteins are
valued molecular indicators, accurate proteomic analysis
is difficult because they rapidly degrade after tissue
devascularization by biopsy or excision [13]. Preserving
phosphoproteins has previously required cumbersome
techniques [8]. The combination of rapid molecular pres-
ervation, laser capture microdissection of the cancer cells,
and highly sensitive proteomic microarray technology [8]
permitted a large number of proteins and pathways to be
evaluated that have not been reported, or are less well
known in relation to anti-HER2 therapy. The correlationreceptor status of primary in ITT-E population (C) by hormone
Figure 3 Protein signal pathway interconnections in baseline biopsies.
Table 3 Summary of all AEs in at least 20% of subjects in any treatment arm (safety population)
Arm 1 trastuzumab N = 32a Arm 2 lapatinib N = 34 Arm 3 trastuzumab + Lapatinib N = 31a
Any AE, n (%) 31 (97) 34 (100) 31 (100)
Diarrhea 17 (53) 29 (85) 31 (100)
Nausea 26 (81) 26 (76) 27 (87)
Rash 14 (44) 28 (82) 26 (84)
Fatigue 22 (69) 24 (71) 24 (77)
Alopecia 21 (66) 23 (68) 18 (58)
Neutropenia 15 (47) 12 (35) 16 (52)
Neuropathy peripheral 15 (47) 19 (56) 14 (45)
Anemia 10 (31) 12 (35) 12 (39)
Hypokalaemia 2 (6) 10 (29) 11 (35)
Epistaxis 7 (22) 10 (29) 10 (32)
Dysgeusia 4 (13) 10 (29) 9 (29)
Myalgia 4 (13) 10 (29) 9 (29)
Pyrexia 3 (9) 8 (24) 9 (29)
Vomiting 7 (22) 15 (44) 9 (29)
Mucosal inflammation 6 (19) 7 (21) 8 (26)
Nail disorder 4 (13) 10 (29) 8 (26)
Cough 8 (25) 3 (9) 7 (23)
Headache 8 (25) 6 (18) 7 (23)
Decreased appetite 5 (16) 7 (21) 7 (23)
Dyspepsia 6 (19) 5 (15) 7 (23)
Dyspnea 4 (13) 6 (18) 7 (23)
Edema peripheral 5 (16) 10 (29) 7 (23)
Stomatitis 5 (16) 7 (21) 7 (23)
Arthralgia 5 (16) 11 (32) 6 (19)
Constipation 12 (38) 8 (24) 6 (19)
Pruritus 3 (9) 7 (21) 6 (19)
Abbreviation: AE adverse event.
a1 patient in the trastuzumab arm and 2 patients in the trastuzumab + lapatinib arms did not receive therapy and therefore were not included in the
safety population.
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these pathways with pCR suggest molecular vulnerabilities
that may provide targets for future individualized treat-
ment trials (see Additional file 5).
Among all the proteins and phosphoproteins measured,
only a small subset showed correlations with pCR. These
included phosphorylated proteins associated with ErbB1/
EGFR, PTEN, FOXO, and Stat5, as well as non-phos-
phorylated proteins associated with autophagy (LC3B,
Beclin1) and extracellular matrix proteolysis (MMP14)
(Table 1). Phosphorylation of EGFR at Tyrosine 1068,
which correlated with no pCR in the lapatinib arm, occurs
during receptor activation, leading to downstream activa-
tion of growth and pro-survival pathway proteins that
may override suppression by lapatinib; although, these
differences were not significant when all baseline samples
(n = 65) were analyzed.
FOXO, a transcription factor, functions as a tumor
suppressor by initiating cell-cycle arrest and apoptosis
after entering the nucleus. Phosphorylation of FOXO
causes export from the nucleus, which inactivates the
tumor-suppressor function. Trastuzumab inhibits HER2-
positive cells by reactivation of FOXO1A [14]. Thus,
FOXO1A and pFOXO levels reflect the activity status of
the HER2/PI3K/AKT network. We found that, in all
treatment arms, pCR tumors had low pFOXO. Thus, a
potential strategy for patients with high pFOXO or low
pPTEN at baseline may be the addition of a PI3K path-
way inhibitor.
Stat5, signal transducer and activator of transcription, is
a transcription factor. After phosphorylation by JAK2,
pStat5 translocates to the nucleus to initiate e-cadherin
transcription, which promotes homotypic adherence bet-
ween breast cells and basement membrane, ie, normal be-
havior [15]. Absent nuclear pStat5 is a negative prognostic
factor in early-stage breast cancer and predicted increased
risk of antiestrogen failure [16]. Studies in chronic lym-
phocytic leukemia (CLL) cells have shown that treatment
with interleukin-21 promotes Stat5 phosphorylation in
natural killer cells which enhanced antibody-dependent
cellular cytotoxicity (ADCC) against rituximab-coated
CLL cells in vitro [17]. Similarly, combined use of anti-
ErbB monoclonal antibodies and erlotinib enhanced
ADCC in wild-type erlotinib sensitive non-small-cell lung
cancer cell lines [18]. Our finding of pStat5 in this study
relates to an intracellular signaling protein influenced in
its function by phosphorylation; nevertheless, we cannot
exclude an indirect effect through ADCC. In our study,
tumors that showed higher levels of pStat5 after 14 days
of trastuzumab (i.e., normal transcription functionality)
had pCR.
Autophagy is a normal cellular process to promote cell
survival under stress, i.e., hypoxia, nutrient deprivation,
loss of adhesion. Autophagy enables the cell to “self eat”to generate ATP from cellular contents and, thereby, sur-
vive during stress or chemotherapy. Autophagy is regu-
lated by a network of cell-signaling proteins including
mTOR, Beclin1, Bcl2, LC3B, and Atg5 [19,20]. The no-
pCR tumors had active autophagy. Another aspect of
autophagy included correlation with MMP-14, which
allows a cell to detach from the basement membrane and
extracellular matrix, and metastasize, i.e., to survive loss of
adhesion. The no-pCR tumors had coordinately increased
MMP-14 and LC3B. In cell models of autophagy-
induced trastuzumab resistance, RNAi-induced knock-
down of LC3B followed by sub-therapeutic doses
of trastuzumab caused synergistic growth inhibition.
Vazquez-Martin et al. noted that this observation has
two implications: 1) hyperactivation of basal autophagy
was a survival mechanism in trastuzumab-refractory
cells; and 2) inhibitors of autophagy, such as chloro-
quine, may reverse or prevent trastuzumab resistance
[19]. Clinical trials evaluating the worth of autophagy in-
hibitors are ongoing (ClinicalTrials.gov: NCT01292408;
NCT 01009437; NCT01023477).
Network analysis of protein-protein interactions among
all the measured proteins in all treatment arms showed
that the number and extent of collaborating signal path-
ways were greater in the no-pCR compared with the pCR
tumors. Complete proteomic network analysis of the
tumors before and after therapy will be reported sepa-
rately. These highly networked tumors may engage alter-
native pathways to survive treatment, thus pretreatment
knowledge of these interconnections might allow preemp-
tive therapy of de novo resistance or before acquired
resistance.
These study findings are constrained by the small
sample size. The protocol specified that patients with paired
biopsy specimens would comprise the biomarker-evaluable
population. Only 49 (63%) in the ITT-E population had bi-
opsies that contained sufficient invasive cancer and met the
required quality control standards for protein assays. The
main limitation imposed by the small paired biopsy sample
size is the inability to evaluate and compare baseline and
day 14 predictive phosphoprotein patterns in each treat-
ment arm.
The small study population may also account for some
of the differences between these results and those of trials
summarized by von Minckwitz et al., particularly response
by HR status [3,10-12,21]. Consistent with other published
studies, we found higher pCR rates in the monotherapy
arms in HR-negative patients [3,10]. The similar pCR rates
in the HR-positive and HR-negative group in the combin-
ation trastuzumab/lapatinib cohorts differs from other
study findings and could be explained by the wide CIs
around the pCR rates due to the small sample size. It is in-
teresting to consider why HR status influences response
to HER2-targeted therapies. Xia et al. suggest that one
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tive/HER2-positive BT474 cells is through de-repression
of FOXO3A and enhanced expression of caveolin-1, both
of which increase ER-mediated transcription, growth, and
survival [22]. In Xia’s model, adding fulvestrant or deple-
ting estrogen from the media reversed the resistance [22].
Nonetheless, von Minckwitz observes pCR is not pre-
dictive of disease-free survival in HER2-positive tumors
that are HR-positive compared with HR-negative [21].
Thus, while improvement in the pCR rate in this subset
has obvious clinical value, e.g., potentially less radical
surgery, improvement in the prognostic value of pCR for
disease-free survival as well as improvement in the rate of
pCR, will require evaluating and targeting multiple path-
ways in addition to ER and HER2. These data offer poten-
tial additional candidate treatment targets and markers to
stratify therapy, including FOX03A, HER3, autophagy,
and PI3 kinase mutation and/or activation status.
Conclusions
The findings from this study, if corroborated in larger
trials, may identify HER2-positive patients at diagnosis
with a high probability of pCR after preoperative anti-
HER2 therapy plus chemotherapy, i.e., tumors with high
ratios of pPTEN/pFOXO1A and PI3K/pFOXO1A and
lack of autophagy (coordinate expression of LC3B with
Beclin1 or MMP14). Patients whose cancers have a high
degree of PI3K signaling or active autophagy at diagnosis
may be candidates for preoperative therapy trials focused
on inhibiting these pathways in addition to HER2.Additional files
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